Jul. 13, 2015
BeiGene, Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, announced on July 13, 2015 that it has treated its first patient in a Phase Ib clinical trial for BGB-283, a second generation B-RAF inhibitor.
This study is designed to determine the efficacy of a daily oral dosing regimen for BGB-283 in solid tumors that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway. The study is being conducted across multiple centers in Australia and New Zealand.
The Phase Ib study being undertaken by BeiGene follows the successful completion of a Phase Ia dose escalation study in patients who have B-RAF or K-RAS mutations. In this study, BGB-283 demonstrated a good safety profile along with promising early clinical activity in patients harboring mutations that previously could not be targeted by first generation B-RAF inhibitors.